Time since SARS-CoV-2 infection and humoral immune response following BNT162b2 mRNA vaccination

Autor: Brent Appelman, Karlijn van der Straten, A.H. Ayesha Lavell, Michiel Schinkel, Marleen A. Slim, Meliawati Poniman, Judith A. Burger, Melissa Oomen, Khadija Tejjani, Alexander P.J. Vlaar, W. Joost Wiersinga, Yvo M. Smulders, Lonneke A. van Vught, Rogier W. Sanders, Marit J. van Gils, Marije K. Bomers, Jonne J. Sikkens, Diederik van de Beek, Marije K Bomers, Justin de Brabander, Matthijs C Brouwer, David TP Buis, Nora Chekrouni, Marit J van Gils, Menno D de Jong, AH Ayesha Lavell, Niels van Mourik, Sabine E Olie, Edgar JG Peters, Tom DY Reijnders, Alex R Schuurman, Jonne J Sikkens, Marleen A Slim, Yvo M Smulders, Alexander PJ Vlaar, Lonneke A van Vught, W Joost Wiersinga
Přispěvatelé: Internal medicine, AII - Infectious diseases, ACS - Diabetes & metabolism, ACS - Atherosclerosis & ischemic syndromes, Center of Experimental and Molecular Medicine, Graduate School, Medical Microbiology and Infection Prevention, Intensive Care Medicine, ACS - Microcirculation, Infectious diseases, APH - Personalized Medicine, APH - Health Behaviors & Chronic Diseases, ACS - Pulmonary hypertension & thrombosis
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Zdroj: EBioMedicine, 72:103589. Elsevier BV
EBioMedicine, Vol 72, Iss, Pp 103589-(2021)
Amsterdam UMC COVID-19 S3/HCW study group 2021, ' Time since SARS-CoV-2 infection and humoral immune response following BNT162b2 mRNA vaccination ', EBioMedicine, vol. 72, 103589 . https://doi.org/10.1016/j.ebiom.2021.103589
ISSN: 2352-3964
DOI: 10.1016/j.ebiom.2021.103589
Popis: Background: To optimise the use of available SARS-CoV-2 vaccines, some advocate delaying second vaccination for individuals infected within six months. We studied whether post-vaccination immune response is equally potent in individuals infected over six months prior to vaccination. Methods: We tested serum IgG binding to SARS-CoV-2 spike protein and neutralising capacity in 110 healthcare workers, before and after both BNT162b2 messenger RNA (mRNA) vaccinations. We compared outcomes between participants with more recent infection (n = 18, median two months, IQR 2-3), with infection-vaccination interval over six months (n = 19, median nine months, IQR 9-10), and to those not previously infected (n = 73). Findings: Both recently and earlier infected participants showed comparable humoral immune responses after a single mRNA vaccination, while exceeding those of previously uninfected persons after two vaccinations with 2.5 fold (p = 0.003) and 3.4 fold (p < 0.001) for binding antibody levels, and 6.4 and 7.2 fold for neutralisation titres, respectively (both p < 0.001). The second vaccine dose yielded no further substantial improvement of the humoral response in the previously infected participants (0.97 fold, p = 0.92), while it was associated with a 4 fold increase in antibody binding levels and 18 fold increase in neutralisation titres in previously uninfected participants (both p < 0.001). Adjustment for potential confounding of sex and age did not affect these findings. Interpretation: Delaying the second vaccination in individuals infected up to ten months prior may constitute a more efficient use of limited vaccine supplies. Funding: Netherlands Organization for Health Research and Development ZonMw; Corona Research Fund Amsterdam UMC; Bill & Melinda Gates Foundation.
Databáze: OpenAIRE
Externí odkaz: